Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

February 18, 2019

Study Completion Date

March 1, 2019

Conditions
Poor Ovarian Response
Interventions
DRUG

Androgen priming

"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"

Trial Locations (1)

Unknown

Lan N Vuong, Ho Chi Minh City

All Listed Sponsors
lead

Mỹ Đức Hospital

OTHER

NCT03447184 - Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study | Biotech Hunter | Biotech Hunter